Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.85 |
| ▸ | KIT | P10721 | 9/20 | 0.85 |
| ▸ | PDGFRA | P16234 | 9/20 | 0.85 |
| ▸ | FLT1 | P17948 | 3/20 | 0.85 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.85 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.85 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.85 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.85 |
| ▸ | FLT4 | P35916 | 2/20 | 0.85 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.85 |
| ▸ | PLK4 | O00444 | 1/20 | 0.85 |
| ▸ | AURKA | O14965 | 1/20 | 0.85 |
| ▸ | GAK | O14976 | 1/20 | 0.85 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.85 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.85 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.85 |
| ▸ | CA12 | O43570 | 1/20 | 0.85 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.85 |
| ▸ | JAK2 | O60674 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pazopanib SCHEMBL3173301 | 0.93 | KDR (0.95) | KDRKITPDGFRAFLT1ABCB11 | |
| Pazopanib SCHEMBL29392503 | 0.92 | KDR (1.00) | KDRKITPDGFRAFLT1ABCB11 | |
| Pazopanib SCHEMBL588608 | 0.92 | KDR (1.00) | KDRKITPDGFRAFLT1ABCB11 | |
| SCHEMBL10151223 | 0.92 | ABCB11 (1.00) | KDRKITPDGFRAFLT1ABCB11 | |
| Pazopanib SCHEMBL159487 | 0.91 | KDR (0.98) | KDRKITPDGFRAFLT1ABCB11 | |
| Pazopanib SCHEMBL29386934 | 0.91 | KDR (0.98) | KDRKITPDGFRAFLT1ABCB11 | |
| Pazopanib SCHEMBL29520402 | 0.91 | KDR (0.98) | KDRKITPDGFRAFLT1ABCB11 | |
| SCHEMBL16085074 | 0.91 | KDR (0.84) | KDRKITPDGFRAFLT1ABCB11 | |
| Pazopanib SCHEMBL935692 | 0.91 | KDR (0.97) | KDRKITPDGFRAFLT1ABCB11 | |
| SCHEMBL11913949 | 0.89 | KDR (0.81) | KDRKITPDGFRAFLT1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181744-A1 | COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASES | FUDAN UNIVERSITY (CN) | 2023-06-15 | — | — | US | disclosed |
| US-20230181744-A1 | COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASES | FUDAN UNIVERSITY (CN) | 2023-06-15 | — | — | US | disclosed |
| WO-2021213518-A1 | COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASES | 复旦大学 (CN) | 2021-10-28 | — | — | WO | disclosed |
| EP-2608790-A1 | PHARMACEUTICAL COMBINATION OF A VEGFR INHIBITOR AND A MEK INHIBITOR USEFUL FOR TREATING CANCER | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012027438-A1 | PHARMACEUTICAL COMBINATION OF A VEGFR INHIBITOR AND A MEK INHIBITOR USEFUL FOR TREATING CANCER | GLAXOSMITHKLINE LLC (US) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181744-A1 | COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASES | MAP1LC3B, MAP1LC3A, SQSTM1 | KDR 2776/4885KIT 4857/4885PDGFRA 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.